Overcoming Misinformation Starts With 1 Person at a Time
This Oncology News Central article covers phase 3 TALAPRO-3 trial results showing that talazoparib plus enzalutamide improved radiographic progression-free survival in men with HRR gene-altered metastatic castration-sensitive prostate cancer